Apollomics (APLM) Non-Current Assets (2021 - 2025)
Apollomics' (APLM) quarterly Non-Current Assets came in at $663000.0 in Q4 2025, down 76.58% year-over-year from $2.8 million in Q4 2024, and down 33.03% quarter-over-quarter from $990000.0 in Q2 2025.
Analysis
Apollomics (APLM) Non-Current Assets (2021 - 2025) Analysis & Trends
Apollomics (APLM) has reported Non-Current Assets for 5 consecutive years, with $663000.0 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Non-Current Assets fell 76.58% year-over-year to $663000.0 in Q4 2025; TTM through Dec 2025 was $663000.0, a 76.58% decrease from a year earlier, with the FY2025 full-year figure at $663000.0, down 76.58% from the prior year.
- Non-Current Assets was $663000.0 for Q4 2025 at Apollomics, down from $990000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $24.1 million in Q4 2021 and troughed at $663000.0 in Q4 2025.
- A 5-year average of $10.9 million and a median of $10.8 million in 2023 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets retreated 14.06% in 2022 and plunged 83.93% in 2025, its largest moves.
- Over 5 years, Non-Current Assets stood at $24.1 million in 2021, then declined by 14.06% to $20.7 million in 2022, then declined by 25.25% to $15.5 million in 2023, then plunged by 81.69% to $2.8 million in 2024, then sank by 76.58% to $663000.0 in 2025.
- The last three Non-Current Assets figures came in at $663000.0 (Q4 2025), $990000.0 (Q2 2025), and $2.8 million (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Apollomics | 34.50 Mn | 31.23 Mn | - | 663,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 663,000.00 |
| Jun 30, 2025 | 990,000.00 |
| Dec 31, 2024 | 2.83 Mn |
| Jun 30, 2024 | 6.16 Mn |
| Dec 31, 2023 | 15.46 Mn |
| Jun 30, 2023 | 16.00 Mn |
| Dec 31, 2022 | 20.69 Mn |
| Dec 31, 2021 | 24.07 Mn |